Baseline characteristics of the registry data groups
. | Nontransplantation . | Transplantation . | . | . | Statistical differences . | . | . | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
Characteristic . | MDS IMRAW . | MDS IBMTR . | MDS FHCRC . | AML IBMTR . | P* . | P† . | P‡ . | ||||
No. of patients | 184 | 193 | 67 | 230 | |||||||
Age, y, median (range) | 49.8 (18-60) | 39.4 (18-59) | 45.6 (20-60) | 41.7 (18-60) | <.0001 | <.0001 | NS | ||||
Male sex, % | 58.2 | 53.4 | 59.7 | 53.5 | NS | NS | NS | ||||
FAB subtype, % | <.0001 | NS | NA | ||||||||
RA | 51.6 | 30.57 | 38.81 | NA | |||||||
RARS | 16.9 | 2.07 | 4.48 | NA | |||||||
RAEB | 25.0 | 28.5 | 37.31 | NA | |||||||
RAEB-t | 6.5 | 34.72 | 17.91 | NA | |||||||
Unknown | 0 | 4.15 | 1.49 | NA | |||||||
IPSS risk group, % | <.0001 | <.001 | NA | ||||||||
Low | 31.0 | 9.84 | 2.99 | NA | |||||||
Int-1 | 42.9 | 53.37 | 32.84 | NA | |||||||
Int-2 | 20.1 | 17.62 | 46.27 | NA | |||||||
High | 6.0 | 19.17 | 17.91 | NA |
. | Nontransplantation . | Transplantation . | . | . | Statistical differences . | . | . | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
Characteristic . | MDS IMRAW . | MDS IBMTR . | MDS FHCRC . | AML IBMTR . | P* . | P† . | P‡ . | ||||
No. of patients | 184 | 193 | 67 | 230 | |||||||
Age, y, median (range) | 49.8 (18-60) | 39.4 (18-59) | 45.6 (20-60) | 41.7 (18-60) | <.0001 | <.0001 | NS | ||||
Male sex, % | 58.2 | 53.4 | 59.7 | 53.5 | NS | NS | NS | ||||
FAB subtype, % | <.0001 | NS | NA | ||||||||
RA | 51.6 | 30.57 | 38.81 | NA | |||||||
RARS | 16.9 | 2.07 | 4.48 | NA | |||||||
RAEB | 25.0 | 28.5 | 37.31 | NA | |||||||
RAEB-t | 6.5 | 34.72 | 17.91 | NA | |||||||
Unknown | 0 | 4.15 | 1.49 | NA | |||||||
IPSS risk group, % | <.0001 | <.001 | NA | ||||||||
Low | 31.0 | 9.84 | 2.99 | NA | |||||||
Int-1 | 42.9 | 53.37 | 32.84 | NA | |||||||
Int-2 | 20.1 | 17.62 | 46.27 | NA | |||||||
High | 6.0 | 19.17 | 17.91 | NA |
MDS indicates myelodysplastic syndrome; AML, acute myelogenous leukemia; Tx, transplant; FAB, French-American-British Classification of Myelodysplastic Syndrome; RA, refractory anemia; RARS, refractory anemia with ringed sideroblasts; RAEB, refractory anemia with excess blasts; RAEB-t, refractory anemia with excess blasts in transformation; IMRAW, International MDS Risk Assessment Workshop; IBMTR, International Bone Marrow Transplant Registry; FHCRC, Fred Hutchison Cancer Research Center; NS, not significant; and NA, not applicable.
Probability of testing MDS IMRAW versus all transplantations.
Probability of testing MDS IBMTR versus MDS FHCRC.
Probability of testing MDS versus AML transplantation.